ClinicalTrials.gg
RecruitingNCT07247188Updated Apr 15, 2026

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

A Phase 3 interventional study of PCV21 and 20vPCV in Sickle Cell Disease, sponsored by Sanofi. Recruiting at 7 sites in 2 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
106th of 559
100 · median 31
Started
2026
with 28 others
Phase 3
50 of 733
10 open now
Primary completion
2027-01
later than 63 of 182 live
Registered
706th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 106th largest by planned enrollment of the 559 interventional ones that give a count, is one of 29 that started in 2026, is one of 50 in phase 3, reaches primary completion later than 63 of the 182 other live ones, and was the 706th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

128 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

Read the detailed description

The study duration per participant will be up to 6 months.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle Cell Disease
  • Pneumococcal Vaccine
  • Pneumococcal Conjugate Vaccine
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

AGE

  • Aged 2 to 17 years on the day of inclusion.

TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS

  • Participants who have a documented diagnosis of sickle cell disease (SCD) in their medical record.

SEX, /BARRIER METHOD AND PREGNANCY TESTING REQUIREMENTS

  • A participant is eligible to participate if the participant is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be pre-menarchal or surgically sterile. OR
    • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration. A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before the study intervention.

  • Assent form has been signed and dated by the participant (based on local regulations), and, if applicable, informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (LAR) and by an independent witness, if required by local regulations.

OTHER INCLUSIONS

  • Participant and parent(s)/LAR are able to attend all scheduled visits and to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

MEDICAL CONDITIONS

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy.
  • History of microbiologically confirmed S. pneumoniae infection or disease.
  • History of seizure or significant stable or progressive neurological disorders such as inflammatory nervous system diseases, encephalopathy, and cerebral palsy.
  • Known systemic to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances.
  • Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent/LAR, contraindicating intramuscular (IM) injection.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection.
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.

For children/adolescents (6 to 17 YoA) only

  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.

PRIOR/CONCOMITANT THERAPY

  • Receipt of at least one dose of 20vPCV.
  • For children aged \< 6 years: receipt of \< 3 doses of pneumococcal conjugate vaccine or any dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23).
  • For children and adolescents aged ≥ 6 years: receipt of PPSV23 \< 5 years before study vaccination or last PCV dose \< 8 weeks before study vaccination.
  • Receipt of any vaccine in the 4 weeks preceding the study intervention administration or planned receipt of any vaccine in the 4 weeks following the study intervention administration, except for US licensed influenza vaccination, which may be received at least 2 weeks before or 2 weeks after study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, as applicable per local recommendations.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Receipt of an oral or injectable antibiotic therapy for any acute illness within 72 hours prior to the first blood draw.

PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE

  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

OTHER EXCLUSIONS For children (2 to 5 YoA) only

  • Being in an emergency setting.
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.

For children/adolescents (6 to 17 YoA) only

  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Investigated Vaccine: PCV21

    Participants will receive 1 intramuscular injection of the pneumococcal vaccine

    Biological: PCV21

  • Active comparator
    Comparator Vaccine: 20vPCV

    Participants will receive 1 intramuscular injection of the pneumococcal vaccine

    Biological: 20vPCV

Interventions

  • BiologicalPCV21

    Investigational pneumococcal conjugate vaccine

  • Biological20vPCV

    20-valent pneumococcal conjugate vaccine

    Also known as: Prevnar 20

06

What researchers measure

Primary outcomes

  1. Number of participants reporting immediate adverse events (AEs)

    Unsolicited (spontaneously reported) systemic AEs after injection of a pneumococcal vaccine

    Time frame: Within 30 minutes post-vaccination

  2. Number of participants reporting solicited injection site and solicited systemic reactions

    Time frame: Up to Day 7 post-vaccination

  3. Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after injection of a pneumococcal vaccine

    Time frame: Within 30 days post-vaccination

  4. Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)

    SAEs and AESIs are collected throughout the study period

    Time frame: From day 0 to day 181

  5. Number of participants with serotype-specific immunoglobulin G (IgG) concentrations for all serotypes included in PCV21

    Ab (antibody) concentrations for each pneumococcal serotype measured by electro-chemiluminescence (ECL) assay

    Time frame: On day 30 post-vaccination

Secondary outcomes

  1. Number of participants with serotype-specific IgG concentrations for all serotypes included in PCV21

    Ab concentrations for each pneumococcal serotype are measured by ECL assay

    Time frame: Pre-vaccination and at 30 days post-vaccination

  2. Number of participants with serotype specific opsonophagocytic activity (OPA) titers for all serotypes included in PCV21

    Serotype specific OPA titers for each pneumococcal serotype are determined by multiplex opsonophagocytic killing assay (MOPA)

    Time frame: On day 30

  3. Number of participants with serotype specific opsonophagocytic activity (OPA) titers for all serotypes included in PCV21

    Serotype specific OPA titers for each pneumococcal serotype are determined by multiplex opsonophagocytic killing assay (MOPA)

    Time frame: Pre-vaccination and at 30 days post-vaccination

07

Study locations

7 of 7 sites recruiting
  • Site # 8400006
    Atlanta, Georgia 30310, United States
    Recruiting
  • Site # 8400002
    Atlanta, Georgia 30322, United States
    Recruiting
  • Site # 8400003
    Omaha, Nebraska 68114, United States
    Recruiting
  • Site # 8400001
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Site # 8400004
    Houston, Texas 77030, United States
    Recruiting
  • Site # 2140001
    Santo Domingo, Dominican Republic
    Recruiting
  • Site # 2140003
    Santo Domingo, Dominican Republic
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 35 phase 3 interventional studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 61. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 25, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Jan 7, 2027
CompletionEst.
Jan 7, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247188
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Jan 20, 2026
Primary completion
Jan 7, 2027 (estimated)
Completion
Jan 7, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Trial Transparency email recommended (Toll free number for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. Option 6
Clinical Sciences & Operations Study Director
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion